18:34 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

G1 falls as trilaciclib shows myeloprotective effects but no response benefit in first-line SCLC

G1 Therapeutics Inc. (NASDAQ:GTHX) shares fell $4.54 (11%) to $35.39 Nov. 27 after Phase II data showed that the company’s trilaciclib plus Tecentriq atezolizumab and chemotherapy failed to show an improvement in overall response rate...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
23:26 , Nov 27, 2018 |  BC Extra  |  Clinical News

G1 falls as trilaciclib shows myeloprotective effects but no response benefit in first-line SCLC

G1 Therapeutics Inc. (NASDAQ:GTHX) shares fell $4.54 (11%) to $35.39 Tuesday after Phase II data showed that the company’s trilaciclib plus Tecentriq atezolizumab and chemotherapy failed to show an improvement in overall response rate (ORR)...
16:57 , Oct 26, 2018 |  BC Week In Review  |  Company News

NICE recommends against abemaciclib for untreated breast cancer

The U.K.'s NICE issued draft guidance recommending against the use of Verzenio abemaciclib from Eli Lilly and Co. (NYSE:LLY) in combination with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer. NICE said...
16:30 , Sep 21, 2018 |  BC Week In Review  |  Financial News

G1 prices $180M follow-on

G1 Therapeutics Inc. (NASDAQ:GTHX) raised $180 million in a follow-on that priced after hours on Sept. 18. G1 sold 3 million shares at $60 in an offering underwritten by J. P. Morgan, Cowen, Needham, Wedbush,...
17:34 , Sep 19, 2018 |  BC Extra  |  Financial News

argenx, G1 price follow-ons, CRISPR proposes

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) and G1 Therapeutics Inc. (NASDAQ:GTHX) raised $300.6 million and $180 million, respectively, in follow-ons that priced after hours Tuesday. argenx sold 3.5 million ADSs at $86.50, an 8% discount to its...
18:56 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
21:36 , Aug 23, 2018 |  BC Extra  |  Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
17:06 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals July 26, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended...
22:08 , Jul 27, 2018 |  BC Extra  |  Company News

CHMP positive on patisiran, Symkevi, Humira and Neulasta biosimilars

EMA's CHMP recommended a number of approvals Friday, including Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Symkevi tezacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a handful of cancer therapies and three biosimilars. The committee recommended approval...